Symdeko (Ivacaftor)

Generic Name

Ivacaftor

Brand Names

Symdeko, Kalydeco, Trikafta, Orkambi

FDA approval date: January 31, 2012

Classification: Cystic Fibrosis Transmembrane Conductance Regulator Potentiator

Form: Tablet, Kit, Granule

What is Symdeko (Ivacaftor)?

TRIKAFTA is indicated for the treatment of cystic fibrosis in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene or a mutation in the CFTR gene that is responsive based on clinical and/or in vitro data [see Clinical Pharmacology (1.

Approved To Treat

Cystic Fibrosis

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis

Enrollment Status: Recruiting

Publish Date: April 14, 2026

Intervention Type: Drug

Study Phase: Phase 1

Summary: The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).

A Phase 2a Randomized, Double-blind, Placebo-controlled Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Physician-prescribed Trikafta® in People With Cystic Fibrosis Who Are Homozygous for the F508del Mutation

Enrollment Status: Recruiting

Publish Date: March 02, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta.

CFTR Biomarker Studie Bei Patient*Innen Mit Mukoviszidose Und CFTR-Modulatortherapie

Enrollment Status: Recruiting

Publish Date: February 24, 2026

Intervention Type: Drug

Summary: This observational study evaluates the effect of therapy with cystic fibrosis transmembrane regulator (CFTR) modulators on CFTR function measured by the CFTR biomarker intestinal current measurement (ICM), nasal potential difference (NPD) and sweat chloride in a post-approval setting in patients with cystic fibrosis (CF).

View All Clinical Trials